Corrigenda

Abstract

HaemophiliaVolume 14, Issue 3 p. 670-670 Free Access Corrigenda This article corrects the following: Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors W. K. HOOTS, L. S. EBBESEN, B. A. KONKLE, G. K.-H. AUERSWALD, H. R. ROBERTS, J. WEATHERALL, J.-M. FERRAN, R. C. R. LJUNG, , Volume 14Issue 3Haemophilia pages: 466-475 First Published online: February 12, 2008 First published: 28 April 2008 https://doi.org/10.1111/j.1365-2516.2008.01770_1.xAboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat In the below article [1], the corrected text under the section “HRQoL” should read as: Prophylaxis with rFVIIa more than halved the proportion of days in hospital attributable to bleeding versus on-demand therapy during the pre-prophylaxis period (P = 0.0026; Fig. 1a). The median number of days of bleeding-related hospitalization decreased from 9.5 to 1.5 days in 3 months. There were non-significant trends towards the effect of rFVIIa prophylaxis being maintained during the post-prophylaxis period, with median hospitalization rates of 9%, 2% and 6% during the pre-prophylaxis, prophylaxis and post-prophylaxis periods, respectively. The proportion of days absent from school or work (Fig. 1b) was also significantly less (P = 0.0127) during rFVIIa prophylaxis than the pre-prophylaxis period (means respectively are 16.7% versus 38.7%). The median number (rates) of absentee days from school/work decreased from 18.5 days (33%) during the pre-prophylaxis period to 4.5 days (8%) with rFVIIa prophylaxis and 8.5 days (20%) during post-prophylaxis. Overall use of mobility aids remained unchanged throughout the trial, with patients requiring mobility aids on 28.3%, 27.5% and 26.2% of days in the pre-prophylaxis, prophylaxis and post-prophylaxis periods, respectively. References 1 Hoots WK, Ebbesen LS, Konkle BA, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466– 75. 2 Neeta S, Nupur G, Shikha S, Deepika D, Suneeta M. Corpus luteal hemorrhage: an unusual manifestation of congenital factor XIII deficiency. Haemophilia 2008; 14: 667– 8. Volume14, Issue3May 2008Pages 670-670 ReferencesRelatedInformation